User talk:Djbenn9

Howard Feldman, MD, Neurologist
Dr. Howard Feldman is a Professor in the Department of Neurosciences and Dean of Alzheimer’s and Neurodegenerative Research at UC San Diego. He directs the Alzheimer’s Disease Cooperative Study (ADCS), a national grant-funded network and coordinating center that has a current portfolio of 10 clinical trials.

From 2009-2011, Dr. Feldman took a leave from his academic appointment at UBC to take on a senior leadership role as therapeutic area head for neuroscience global clinical research at Bristol-Myers Squibb, where his research focused on developing novel pharmaceutical therapies for neurodegenerative and other neurological/psychiatric disorders.

Dr. Feldman has made contributions in scientific discoveries and clinical research studies focused on aging, mild cognitive impairment/Alzheimer’s disease (AD), frontotemporal dementia (FTD) and diagnostic/therapeutic trials. He has led numerous international clinical trials in AD resulting in important original data and informing care across the continuum of the disease. In the field of frontotemporal dementia, he has contributed to the discoveries of the progranulin (Nature 2006) and C9ORF72 (Neuron 2011) genetic mutations as well as to the elucidation of TDP43. He has helped lead the international working group that has reframed diagnostic criteria for Alzheimer’s disease that have re-conceptualized the disease and transformed the approach to clinical trials (Lancet Neurology 2007, 2011, 2014, 2016, 2021).

His career contributions have been profiled in Lancet Neurology in 2007. He has been named by Web of Science Clarivate Analytics as a ‘highly cited’ neuroscientist and among ‘the world’s most influential scientific minds’ (2008-18). He was appointed as a Fellow of the Canadian Academy of Health Sciences and the American Academy of Neurology in 2008. In 2019, he was also ranked #1 PI in Neurosciences funding from NIH by Blueridge Institute for Medical Research Djbenn9 (talk) 00:45, 3 October 2022 (UTC)